Serum ultrafiltrates (SUF) from human patlents with dllrerent types of ~ contaha a bloddna factor (BF) that inhiblts the cytolytic activity ofhumaa tamor necrosls factor a (TNF-a) 
af 28 kDa OD mludng IOdium dodecyl salfate/poly.:rylandde gd eledropboresk(SDS/PAGE). Theactivematerialwaspariftedto bomogeneity by a comblnatioo of allinity cbromatocraPby, PAGE, and blgh-premure liquid c:bromatognq>hy. Amino add sequence analysis revealed that BF ls dertved from the membnne TNF receptor. Purifted BF blocks the lytlc adivity of recomblmmt human and mome TNF·a and ruomblnant human lymphotoxln oo murine L929 cells in l'itro. Bowever, BF inhibiSs the lytlc activlty af TNF ·ct more dfectmly thlD lt does that of ~ toxln. 1be BF a111o lnhlblts the neaGdDng acdYlty of rec:embinaot human TNF-a wben ~ IDto eslablhbed cutueous Metb A tumors In BALB/ c mice. 1be BF may have an lmporUnt role In (i) the rquladon and coatrol af TNF-a and lympbotoxin actlvlty In cancer paöeats, (ii) lnteraction between the tumor and the host antitumor medwUsms, and (ib) use of systemirally admjnistemf TNF-a in clinlcal trials wlth human cancer patients.
Tumor necrosis factor a (TNF-a) and lymphotoxin (LT or TNF-ß) are two interrelated proteins that, in native form, are homotrimers of 17-and 17.5-kDa peptides, respectively (1, 2) . Their genes are Jocated in tandcm within the major histocompatibility complex of mammals (3) . Wbile lymphotoxin is predominantly produced by lymphocytes (4) , TNF-a is produced by macrophages, lymphocytes, and other cells in selected situations (5) . These cytokines have many cffects in vitro whcn tested on different kinds of cells (6) such as (1) growth inbibition or lysis oftransformed cells, (il) activation of phagocytic cells, (iir) upregulation of various cell surface proteins, and (iv) control of the development and exprcssion of ceU-mediated antitumor responses. They also can cause a spectrum of reactions in vivo (7) (8) (9) , some of which include (i) necrosis of tumors, (il) leukocytosis and inflammation, and (iir) wasting and shock. The activities attributed to these cytokines have evoked interest in the potential use of these molecules as anticancer agents (10) . However, clinical trials to date indicate that systemically administercd TNF-a has, at best, limited clinical cfficacy (11) .
We recently demonstrated that serum ultrafiltrates (SUF) obtained from patients with various types of cancer contained factor(s) that could inhibit the cytolytic activity of both recombinant human TNF-a and lymphotoxin on L929 ceUs in vitro (12, 13) .
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In the present study, the active material in the SUF was purified and shown to be a 28-kDa protein and to express the biologic activity measured in SUF. This material termed "blocking factor" (BF) has N-terminal amino acid sequcnces similar to a soluble TNF-binding factor identified prcviously in the urine of postmenopausal women and patients with chronic renal failurc (14) (15) (16) (17) . We have demonstrated (18) that BF is the extracellular N-tenninal domain of a protein derived from the membrane TNF receptor.
MATERIALS AND MEmODS
SUF. All SUF were obtained from Rigdon Lentz at the John Kennedy Hospital (Indio, CA). Tue ultrafiltration procedure has been described (12) . Patients used in these studies bad advanced stages of cancers of prostate, breast, brain, and bowel. They had not received chemotherapy for 1-2 months prior to ultrafiltration.
Assays for Activlty of TNF, Lymphotoxin, and BF. The rccombinant human TNF-a and lymphotoxin were donated by Genentech, and recombinant murine TNF was purchased from Amgen Biologicals. Activity was assayed on L929 mouse fibroblasts as described (19) .
To assay the activity ofthe BF, monolayers ofnondividing L929 cells (8 x 1<>4 cells per well) were incubated in a final volurne of 200 µl with 1 µg of actinomycin D (Sigma) per ml.
V arious dilutions of TNF-a or lymphotoxin and 25 µl of sample solution containing either BF or control medium were added to the L929 cells in 96-well microplates. After 18 hr in 5% COi/ 95% air at 37"C, the media were aspirated and cells were stained with 1% crystal violet for 5 min, washed with water, and solubilized with 100 µl of 100 mM HCI in methanol. Adherent cell number is determined by the OD at (i()() nm measured in an EAR 400 AT ELIZA plate reader (SLT-Labinstruments, Salzburg, Austria). Neutralization ofTNF in vitro activity with rabbit antibody was perfonned by the method of Kashiwa et al. (20) . One unit of inlubition is calculated by the following formula: 1 unit = [LD 50 (TNF or lymphotoxin + sample) -LDso (TNF or Jymphotoxin alone))/LD 50 (TNF or lymphotoxin alone).
TNF-Alftnlty Column. SUF from patients with the highest levels ofBF activity as measurcd in the L929 cytolytic assay (13) werc pooled. A total of thrce separate purification runs were performed on a total of 52 liters of SUF. Proteins in the SUF were precipitated by the addition of crystalline, ultrapure ammonium sulfate (Fisher) to reach 80% saturation and then were incubated ovemight at 4°C. The precipitate was collected by centrifugation and then solubilized in 2 liters of phosphate-buffered saline (PBS; 0.01 M phosphate/0.15 M NaCl, pH 7.2). The solution was dialyzed against three changes oflO liters each oflO mM Tris·HCl/50 mM NaCI, pH 7.4, overnight at 4°C.
A TNF-affinity column was preparcd by coupling 4 mg of TNF-a to 1.0 g of CNBr-activated Sepharose 4B (Pharmacia) in coupling buffer (0.1 M NaHC0 3 /l M NaCI, pH 9.0). The TNF-Sepharose was poured into a 5-ml column and was washed three times in 100 ml of 1 M NaCl/ 0.1 M sodium acetate, pH 8.0, and 1 M NaCl/0.1 M boric acid, pH 4.0, altemately before use. The 2 liters of dialyzed sample was applied to the TNF-affinity column at a flow rate oflO ml/hr. Tbc column was then washed with 50 mM Tris·HCl (pH 8.0) until the absorbance at 280 nm of the output solution was negative. The column was then eluted with three consecutive 3-ml aliquots of 0.2 M glycine·HCl (pH 2.5), and the total eluate was dialyzed against PBS at 4°C for 16 hr. Protein concentration in all samples was determined by absorbance at 260/280 run in a Beckman spectrophotometer.
Reduclng and Nonreduclng Sodium Dodecyl Sulfate/ Polyacrylamlde Gel E1ectrophoresls (SDS/PAGE). A total of 1-10 µg of protein from the affinity column eluate was subjected to both reducing and nonreducing SOS/PAGE as descnbed by Laemmli (21). Protein was visualized by silver staining (22) . The eluate was also subjected to nonreducing SOS/PAGE in which the individual lanes were cut into 4-mm slices (16, 23) . Proteins in each slice were eluted by overnight incubation in 1 ml of 10 mM Tris·HCl/1 mM EDT A, pH 7 .4. The eluates from gel slices were dialyzed overnight against PBS to remove SOS and then were assayed for BF activity as described in the preceding section. Tbc molecular mass of BF was calculated by comparison with coelectrophoresed samples from an electrophoresis calibration kit (Pharmacia) with the following markers: phosphorylase b, bovine scrum albumin, ovalbumin, carbonic anhydrasc, soybean trypsin inhibitor, and a-lactalbumin.
Amino Acid Sequeoce Analysis. Samples of eluate from the TNF-affinity column were next separated by HPLC. Samples were loaded on small (1.5 mm x 50 mm) glass columns packed with 15-µ.m C 18 reversed-phase material (J. T . Baker). Proc. Natl. Acad. Sei. USA 87 (1990) The column was eluted on an HP 1090 high-pressure liquid chromatograpb with a linear gradient of 1-60% n-propyl alcohol in 0.1% CF 3 COOH (Applied Biosystems) in water at a rate of 0.2 ml/ min. Each protein peak was collected and sequenced. Sequence analysis was conducted by Edman degradation on a gas/liquid-phase prototype sequencer (patent no. EP0257735). The liquid-pbase buffer was 0. 
RF.sULTS
Purification of TNF /Lympbotoxin BF. Three individual lots of SUF were purified as described in Materials and Methods. The equivalent at 20 liters (160-300 g of protcin) of the SUF was passed through the TNF-affinity column, and about 25,000 units of the BF (200-500 µ.g of protein) were routinely eluted from the TNF-affinity column. Tbc eluate from the TNF-affinity column derived from each of the lots contained multiple bands when subjected to nonreducing SOS/PAGE as shown in Fig. lA . Tbc proteins were eluted from slices of the other half of this gel and testcd in the TNF/lymphotoxin BF assay. As shown in Fig. lB , the activity against both TNF-cr and lymphotoxin was localized to a single peak (between slice no. 8 and 10) (Fig. lB Inset) . Tbc blocking activity against lymphotoxin was about 1 order c LT -28 kDa 3 4 Dislan"" lrom lho orlgin, cm Flo. 1 . Isolation of TNF / lymphotoxin BF from the SUFs of cancer patients. The SUF was passed over and eluted from a TNF-affinity column. A sample ofthe eluate was then subjected to horizontal electrophoresis in nonreducing SOS/ PAGE. The gel was sliced into two sections, and one section was stained by the silver method (A). The other half was cut into 4-mm slices, and the protein was eluted and tested for its ability to block TNF-a-and lymphotoxin (L T)-induced lysis of L929 cells (B). The inhibition in both B and in B /nset represents the level of blocking activity in individual gel slices. Material eluted from nonactive slice no. 25 and the peak ofblocking activity in slice no . 9 were reelectrophoresed in reducing SOS/ PAGE. Silver-stained gels of these fractions are shown in C. Lanes: left, no. 25; right, no . 9. of magnitudc wcalccr than against TNF·a. An activc and an inactivc fraction from thc nonrcducins SOS/PAGE wcre subjcctcd to furthcr clcctrophoresis in a reducins SOS/ PAGE gcl, and a singlc band of28 kDa in thc activc fraction was dctcctcd by silvcr stainins (Fig. lC) .
Amino Acid Seqmndng. Approximatcly half of thc eluatc from thc TNF affinity column was subjccted to further scpa· ration on HPLC. A total of thrcc protcin pcalcs wcre scqucntially clutcd from thc HPLC column. Each pcalc protcin was collcctcd and scquenccd on a prototypc scqucnccr (patent no. EP025n35). Thc amino acid scqucnccs obtaincd wcre thcn comparcd with thc protcin scqucnccs in thc data basc by usins thc DFASTP program. Thc sequcnce from thc first pcalc was thc only unknown scqucncc. All remaining pcaks are known scrum protcins (immunoglobulins and transfcrrin). Thc scqucncins data for thc BF was obtaincd from two separate purification lots (Fig. 2, linc a) (17) (Fig. 2, linc b) and diffcrs at positions 4, 14, 18, and 19 from thc 2~residue N-tcnninal amino acid sequcncc publishcd by Olsson et al. (15) ( Fig. 2, line c) .
In Vill'o Acth1ty of BF ApiDlt Human and Murlne TNF. The activity of BF derivcd from thc TNF·affinity column fraction was tcsted against recombinant murinc and human TNF-a. The rcsults in Fig. 3A show that BF inhibited the cytolytic activity of both rccombinant human and murine TNFs. In contrast, rabbit anti-human and anti·mouse TNF antibodies neutralizcd only thc spccific TNF·a (Fig. 3A. ). tumor·bearins animals were divided into three groups, each containing four animals: (i) one group was ittjected i.t. with PBS, (ii) a second group was irtjectcd i.t. with TNF-a in PBS, and (iir) the last group was irtjected i.t. with TNF·a and BF derivcd from the TNF·affinity column fraction. All irtjections were madc in the samc final 100.µl volume. TNF causcd central nccrosis ofthc transplantcd tumors. Tumor nccrosis was measured over a 72-hr pcriod. Tbc photoaraphs in Fig.  3 illustratc thc result 36 hr aftcr irtjcction. Necrosis was clcarly evident at 36 hr in TNF·a trcated tumors (Fig. 3Bb) .
BF Elfects on TNF·lnduced Necrolls of
In contrast, tumors treatcd with TNF and BF did not cxhibit the TNF-induced necrosis (Fig. 3Bc) cytolytic activity of recombinant human TNF-a and, to a lesser extent, recombinant human lymphotoxin in vitro (13) .
In this study, we pwified this material to homogeneity, detennined its molecular weight in SDS/ PAGE, and obtained a partial N-tenninal amino acid sequence. The apparent molecular mass of the BF in SDS/P AGE is 28 kDa. lt appears to be slightly smaller than the molecular mass reported (30 kDa) for other TNF-binding factors (15, 17) . The partial N-termina1 amino acid sequence is identical to the 5-residue N-tenninal amino acid sequence reported by Engelmann et al. (17) and differs at positions 4, 14, 18, and 19 from the 20-residue N-tenninal amino acid sequence published by Olsson et al. (15) .
Engelmann has postulated that the TNF BF in urine from postrnenopausal women is the membrane TNF receptor (17) . Recently, we finished sequencing a TNF receptor cDNA clone obtained from human placental cDNA libraries, using degenerative probes deduced from the amino acid sequences ofTNF BF derived from SUF (18) . The nucleotide sequence has an open reading frame that can be translated to a peptide of 455 amino acids with a calculated molecular mass of 55 kDa. In the same joumal Lesslaure and coworkers (25) reported an identical sequence of a cDNA for TNF membrane receptor. Collectively, these data suggest that all ofthe soluble BF isolated to date are apparently derived from the 55-kDa TNF membrane receptor (18) . Thus, the BF in the serum from cancer patients appears tobe a fragment derived from the TNF membrane receptor. A second possibitity is that BF is produced by alternative mRNA splicing. However, our preliminary data derived from Northem blotting analysis of mRNA prepared from different human cell lines does not support this possibility.
lt has been proposed by several authors (26, 27 ) that regulation of specific membrane receptors could serve as a mechanism of cytokine regulation. The SUF BF might be an example of this lcind of regulation. The inhibitory activity of BF may be exerted by binding to the TNF and the lymphotoxin so that these cytokines can no longer interact with the relevant cell and tissue receptor(s). The finding that the BF can block the cytolytic activity of recombinant mouse TNF suggested that the active binding sites between the BF and the TNF has been evolutionarily conserved. Our finding that BF can inhibit the necrotizing activity ofTNF in vivo is very significant; however, additional studies will have tobe conducted to further support this concept. These studies may have to wait until recombinant BF is available to provide the quantity of purified materials necessary to test this question.
The mechanism(s) that generates TNF BF and the significance of this material in the serum of cancer patients is not yet clear. If it is derived from the tumor, it could represent a means of inhibitory host anti-tumor mechanisms, and if it is from normal tissues, it could be a natural means of control of these cytokines. Only additional studies will resolve this question; however, BF in these patients may be very important to our understanding of cytokine regulation, pathogenesis, and tumor-host interaction. Finally, the presence ofBF in the serum of cancer patients may affect the use of sysProc. Natl. Acad. Sei. USA 87 (1990) temicaJly administered TNF in clinicaJ trials with cancer patients.
